The gut microbiota are prominent in preserving intestinal environmental homeostasis and
managing human health, and their dysbiosis has been directly related to many kinds of …

Oral administration of probiotics orchestrates the balance between intestinal microbes and
the immune response. However, effective delivery and in situ colonization are limited by the …

Inflammatory bowel diseases (IBDs) refer to multifaceted disorders in the intestinal
microenvironment and microbiota homeostasis. In view of the broad bioactivity and high …

Despite the great progress of current bacterially based biotherapeutics, their unsatisfying
efficacy and underlying safety problems have limited their clinical application. Herein …

Patients with inflammatory bowel disease (IBD) always suffer from severe abdominal pain
and appear to be at high risk for colorectal cancer. Recently, the co-delivery of targeted …

Probiotic-based therapies have shown great potential in the prevention and treatment of
many diseases by positively regulating intestinal flora homeostasis. However, the efficacy of …

Manipulation of gut microbiota by bacterial metabolites has shown protective effects against
colitis; while the efficacy is strictly limited by the poor oral delivery efficiency and single drug …

Microbiota‐based therapeutics offer innovative strategies to treat inflammatory bowel
diseases (IBDs). However, the poor clinical outcome so far and the limited flexibility of the …

The clinical application of orally delivered probiotics as live therapeutics in the treatment of
colitis is hampered by suboptimal bacterial bioactivity and inadequate gut retention. Here …

Transplanting beneficial bacteria to gut microbiome can positively modulate microbiome
composition and is a promising strategy to prevent and treat diseases. However, oral …